Rossari Biotech Reports 13% Revenue Growth in Q3 FY26 Results
Filing Summary
Rossari Biotech Limited announced its Q3 FY26 financial results, reporting a 13% increase in revenue from operations to Rs. 582 crore compared to Q3 FY25. The company’s EBITDA rose by 6% to Rs. 69 crore, while PAT increased by 3% to Rs. 33 crore. For the nine months ending December 31, 2025, revenue grew by 14% to Rs. 1,712 crore. The company received board approval for new manufacturing facilities in Saudi Arabia. These developments are part of Rossari’s strategic initiatives to enhance its manufacturing capabilities and expand its market presence.
Rossari Biotech Limited has released its financial results for the third quarter of fiscal year 2026, ending December 31, 2025. The company reported a 13% increase in revenue from operations, reaching Rs. 582 crore compared to Rs. 513 crore in the same quarter of the previous year. The EBITDA for the quarter improved by 6% to Rs. 69 crore, while the EBITDA margin was recorded at 11.8%, down from 12.6% in Q3 FY25. The Profit After Tax (PAT) increased by 3% to Rs. 33 crore, with an Earnings Per Share (EPS) of Rs. 5.9.
For the nine-month period ending December 31, 2025, Rossari Biotech reported a 14% increase in revenue from operations, amounting to Rs. 1,712 crore compared to Rs. 1,501 crore in the previous year. The EBITDA for this period rose by 7% to Rs. 209 crore, with an EBITDA margin of 12.2%, slightly lower than the 13.0% recorded in the same period last year. The PAT for the nine months increased by 1% to Rs. 103 crore, and the EPS stood at Rs. 18.6.
Rossari Biotech’s operational performance was supported by growth across its business segments. The Home, Personal Care and Performance Chemicals (HPPC) segment recorded an 11% year-on-year growth. The Textile Specialty Chemicals (TSC) segment grew by 18%, while the Animal Health and Nutrition (AHN) segment saw a 39% increase. The company continues to focus on expanding its international operations, which contributed to the overall growth.
The company announced that its board has granted in-principle approval for setting up new greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia. These facilities will be established under Rossari International Limited, a wholly-owned subsidiary. The project aims to enhance supply chain resilience and accelerate speed-to-market. The progress of the project will depend on customary evaluations and necessary regulatory approvals. Funding options being considered include equity, debt, internal accruals, or a combination of these.
Rossari Biotech is implementing a phased capacity expansion program across its verticals to enhance manufacturing capabilities. The company is also exploring regional incentives for the new facilities in Saudi Arabia. These strategic initiatives are part of Rossari’s efforts to strengthen its competitive positioning and support long-term growth.
Rossari Biotech Limited is a specialty chemicals manufacturer providing solutions across various industries. The company operates manufacturing facilities in Silvassa and Dahej, offering products for Home, Personal Care and Performance Chemicals, Textile Specialty Chemicals, and Animal Health and Nutrition. Rossari Biotech focuses on expanding its market presence and enhancing its manufacturing capabilities to cater to a diverse range of applications.